Drug Trial Radar · NCT00751881
An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Jul 7, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,169
Actual
Start
Aug 2008
Primary completion
Apr 2012
Study completion Aug 2015
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Sep 12, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study was to assess the effect of two doses of teriflunomide, in comparison to placebo, on the frequency of multiple sclerosis (MS) relapses in participants with relapsing MS. Key secondary objective was to assess the effect of the two doses of teriflunomide, in comparison to placebo, on disability progression. Other secondary objectives were: * To assess the effect of the two doses of teriflunomide in comparison to placebo on: * Fatigue; * Health-related quality of life, a measure of the impact of the participant's health on his or her overall well being. * To evaluate the safety and tolerability of teriflunomide.
Conditions
- Multiple Sclerosis
Interventions
PlaceboDrug
Film-coated tablet Oral administration
TeriflunomideDrug
Film-coated tablet Oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Core Treatment Period: Annualized Relapse Rate (ARR): Poisson Regression EstimateTime frame: Core treatment period between 48 - 152 weeks depending on time of enrollment
Locations
193 sites in 26 countries. Site status is shown where the registry gives one.
Sanofi-Aventis Investigational Site Number 840041
Phoenix, Arizona
Sanofi-Aventis Investigational Site Number 840084
Tucson, Arizona
Sanofi-Aventis Investigational Site Number 840008
Loma Linda, California
Sanofi-Aventis Investigational Site Number 840034
Modesto, California
Sanofi-Aventis Investigational Site Number 840090
Fort Collins, Colorado
Sanofi-Aventis Investigational Site Number 840011
Fairfield, Connecticut
Sanofi-Aventis Investigational Site Number 840013
Maitland, Florida
Sanofi-Aventis Investigational Site Number 840083
Ocala, Florida
Sanofi-Aventis Investigational Site Number 840086
Ormond Beach, Florida
Sanofi-Aventis Investigational Site Number 840025
Sarasota, Florida
Sanofi-Aventis Investigational Site Number 840015
St. Petersburg, Florida
Sanofi-Aventis Investigational Site Number 840033
Sunrise, Florida
Sanofi-Aventis Investigational Site Number 840063
Elk Grove Village, Illinois
Sanofi-Aventis Investigational Site Number 840064
Flossmoor, Illinois
Sanofi-Aventis Investigational Site Number 840039
Fort Wayne, Indiana
Sanofi-Aventis Investigational Site Number 840012
Indianapolis, Indiana
Sanofi-Aventis Investigational Site Number 840016
Des Moines, Iowa
Sanofi-Aventis Investigational Site Number 840069
Clinton Township, Michigan
Sanofi-Aventis Investigational Site Number 840075
Grand Rapids, Michigan
Sanofi-Aventis Investigational Site Number 840061
Traverse City, Michigan
Sanofi-Aventis Investigational Site Number 840076
Minneapolis, Minnesota
Sanofi-Aventis Investigational Site Number 840079
Tupelo, Mississippi
Sanofi-Aventis Investigational Site Number 840088
St Louis, Missouri
Sanofi-Aventis Investigational Site Number 840060
Syracuse, New York
Sanofi-Aventis Investigational Site Number 840029
Charlotte, North Carolina
Sanofi-Aventis Investigational Site Number 840074
Bismarck, North Dakota
Sanofi-Aventis Investigational Site Number 840026
Cincinnati, Ohio
Sanofi-Aventis Investigational Site Number 840078
Dayton, Ohio
Sanofi-Aventis Investigational Site Number 840066
Tulsa, Oklahoma
Sanofi-Aventis Investigational Site Number 840024
Portland, Oregon
Sanofi-Aventis Investigational Site Number 840073
Philadelphia, Pennsylvania
Sanofi-Aventis Investigational Site Number 840022
Philadelphia, Pennsylvania
Sanofi-Aventis Investigational Site Number 840068
Greenville, South Carolina
Sanofi-Aventis Investigational Site Number 840071
Cordova, Tennessee
Sanofi-Aventis Investigational Site Number 840036
Nashville, Tennessee
Sanofi-Aventis Investigational Site Number 840007
San Antonio, Texas
Sanofi-Aventis Investigational Site Number 840006
Bennington, Vermont
Sanofi-Aventis Investigational Site Number 840089
Seattle, Washington
Sanofi-Aventis Investigational Site Number 840020
Charleston, West Virginia
Sanofi-Aventis Investigational Site Number 036005
Bedford Park, Australia
Showing 40 of 193 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.